Acumen Pharmaceuticals Inc

Acumen Pharmaceuticals Inc has a liquidity position characterized by a current ratio of 4.07, indicating strong short-term liquidity. The company holds $53.99 million in cash and equivalents, which is a significant portion of its total assets of $122.83 million. However, the company reported negative operating cash flow of -$115.54 million and free cash flow of -$121.37 million, reflecting ongoing cash outflows from operations. The company's profitability metrics are negative, with a return on equity of -1.72 and a return on assets of -0.99, indicating that it is not generating returns for shareholders or asset holders. These figures are below the industry median for return on equity and return on assets, which are typically positive for companies in the biotechnology and medical research sector. Acumen Pharmaceuticals Inc operates in a single business segment focused on healthcare diagnostics, with no disclosed geographic revenue concentration. The company's revenue is not segmented by geography in the available data, but its operations are primarily based in the United States. The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The company's operating income and net income have been negative, with a net loss of $121.34 million in the latest reporting period. The company's capital expenditures were minimal at -$88,000, suggesting limited investment in physical assets. The risk assessment for Acumen Pharmaceuticals Inc indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.44, suggesting a relatively conservative capital structure. The company has not disclosed any recent events in filings or transcripts that would indicate significant operational or financial changes.